Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am alerting U 2;a minimum 50$ stock at 2 $... CTIX..eom
Monster run to 50$ CTIX. Get aboard. U b warned.eom
To new investors. Stay long on CTIX. Easy 25 bag.. T M later..eom
CTIX is the only OTC stock that will be 50$ a share posted on this board. Thank me later.
YES, easy 25 bagger, possible 100 bagger. Check the 10K...eom
Break out. You want BREAKOUT!!! CTIX
CTIX...enough said..thank me later..eom
CTIX will be a LEGEND of wall street. Mark it...eom
OTC CTIX up today . What else is NEW..eom
CTIX is the tsunami for the next 3 YEARS. Get on board..eom
CTIX up again today. Onward to 50 dollars..eom
CTIX, up again today. 3 year 25 bagger minimum.
Maybe they will release a clarification on the ONE POSSIBLE incident in the 215 person trial. I see most drugs being advertised on TV having side affects as bad as giving you kidney, liver damage , cancer and even death and they received FDA approval.
Aspirin has a sizable list of side effects.
Have a great day.
CTIX shareholder update today. Long term monster in the making..eom
CTIX investor update today. Long term 50 bagger..eom
CTIX investor update today. Going to be big long term..eom
CTIX investor update today. Nice read..eom
That was some funny stuff. Thanks...eom
N.Y. Giants Superbowl bound. Go Eli...eom
OTC's CTIX, HUGE 10K report, LONG TERM MONSTER
OTC's CTIX Awesome 10K report. http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce this update on its recently ...
read full: http://finance.yahoo.com/news/cellceutix-provides-initial-observations-completed-190000867.html
*********************************************************
Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be ...
read full: http://finance.yahoo.com/news/cellceutix-present-rodman-renshaws-16th-151546102.html
*********************************************************
Tue, 02 Sep 2014 11:00:00 GMT ~ Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. ...
read full: http://finance.yahoo.com/news/cellceutix-appoints-dr-barry-schechter-110000360.html
*********************************************************
Tue, 02 Sep 2014 10:29:26 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and
read full: http://biz.yahoo.com/e/140902/ctix8-k.html
*********************************************************
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
OTC's CTIX, HUGE 10K report, LONG TERM MONSTER
OTC's CTIX Awesome 10K report. http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce this update on its recently ...
read full: http://finance.yahoo.com/news/cellceutix-provides-initial-observations-completed-190000867.html
*********************************************************
Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be ...
read full: http://finance.yahoo.com/news/cellceutix-present-rodman-renshaws-16th-151546102.html
*********************************************************
Tue, 02 Sep 2014 11:00:00 GMT ~ Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. ...
read full: http://finance.yahoo.com/news/cellceutix-appoints-dr-barry-schechter-110000360.html
*********************************************************
Tue, 02 Sep 2014 10:29:26 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and
read full: http://biz.yahoo.com/e/140902/ctix8-k.html
*********************************************************
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
OTC's CTIX, HUGE 10K report, LONG TERM MONSTER
OTC's CTIX Awesome 10K report. http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce this update on its recently ...
read full: http://finance.yahoo.com/news/cellceutix-provides-initial-observations-completed-190000867.html
*********************************************************
Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be ...
read full: http://finance.yahoo.com/news/cellceutix-present-rodman-renshaws-16th-151546102.html
*********************************************************
Tue, 02 Sep 2014 11:00:00 GMT ~ Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. ...
read full: http://finance.yahoo.com/news/cellceutix-appoints-dr-barry-schechter-110000360.html
*********************************************************
Tue, 02 Sep 2014 10:29:26 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and
read full: http://biz.yahoo.com/e/140902/ctix8-k.html
*********************************************************
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
We will know in 4-6 weeks. Their antibiotic trial is against Daptomycin by Cubist. They went against the best in the field. If the trial failed CTIX will be a laughingstock with that PR and it would diminish the other group of impressive drugs in their pipelines.
I don't see management putting that much on the line without a hint on the results. They are running multiple trials at world class facilities, mostly at the medical centers cost.
In a matter of weeks I will know if the PR was fluff or a rare opportunity to be holding a stock before it becomes a Juggernaut.
Have a great weekend ronpopeil
Cellceutix to President Obama: We Have The Tools And Will Rise Up To The Challenge To Prevent Antibiotic Resistant Bacteria Becoming A Serious Threat to Public Health
BEVERLY, MA--(Marketwired - Sep 19, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, commends President Barack Obama for signing an Executive Order on Thursday, September 18, ordering federal agencies to launch a concerted effort to combat the growing threat from bacteria that is resistant to antibiotic treatment. The Obama administration’s measures are part of the first major federal effort to confront a public health problem that takes at least 23,000 lives a year and has an estimated annual impact of on the national economy of $20 billion in excess direct health care costs.
See New Executive Actions to Combat Antibiotic Resistance and Protect Public Health: http://www.whitehouse.gov/blog/2014/09/18/new-executive-actions-combat-antibiotic-resistance-and-protect-public-health
Cellceutix may have one of the world’s best technologies for combating antibiotic resistant bacteria in its novel class of antibiotics called defensin mimetics. They are modeled after host defense proteins, the front line of defense in the innate human immune system. The drug destroys bacteria just like the body would naturally by penetrating the bacterial cell wall, rather than via a biochemical approach like most classes of antibiotics do today. This unique mechanism of action reduces the likelihood of bacterial resistance developing to almost nil.
The public is aware of the Ebola virus threat, but may not be as aware of today’s deadly bacteria. Among the deadliest of resistant bacteria and a major threat to public health is Carbapenem-resistant Klebsiella pneumonia, or CRKP. Cellceutix has been targeting this bacteria and expects to shortly release its study findings. The drug, if successful, would be a major breakthrough.
Cellceutix in approximately one and a half months expects to have have top-line data from its Phase 2b trial of its antibiotic Brilacidin for Acute Bacterial Skin and Skin Structure Infections. Cellceutix believes this Presidential Order could not arrive at a better time and is optimistic that the data from the trial will demonstrate that its novel defensin-mimetic platform shreds bacteria quickly with little-to-no chance of resistance developing. Cellceutix believes positive data will position it perfectly to move forward quickly not only with Brilacidin, but its entire defensin-mimetic portfolio with support from the new Presidential Order.
“If we achieve successful data from the recently completed Phase 2 trial, my hope is that people will understand the defensin mimetic’s potential. It’s no longer a world class antibiotic drug, but a world class platform to fight serious public health threats,” commented Leo Ehrlich, Chief Executive Officer of Cellceutix.
Cellceutix to President Obama: We Have The Tools And Will Rise Up To The Challenge To Prevent Antibiotic Resistant Bacteria Becoming A Serious Threat to Public Health
BEVERLY, MA--(Marketwired - Sep 19, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, commends President Barack Obama for signing an Executive Order on Thursday, September 18, ordering federal agencies to launch a concerted effort to combat the growing threat from bacteria that is resistant to antibiotic treatment. The Obama administration’s measures are part of the first major federal effort to confront a public health problem that takes at least 23,000 lives a year and has an estimated annual impact of on the national economy of $20 billion in excess direct health care costs.
See New Executive Actions to Combat Antibiotic Resistance and Protect Public Health: http://www.whitehouse.gov/blog/2014/09/18/new-executive-actions-combat-antibiotic-resistance-and-protect-public-health
Cellceutix may have one of the world’s best technologies for combating antibiotic resistant bacteria in its novel class of antibiotics called defensin mimetics. They are modeled after host defense proteins, the front line of defense in the innate human immune system. The drug destroys bacteria just like the body would naturally by penetrating the bacterial cell wall, rather than via a biochemical approach like most classes of antibiotics do today. This unique mechanism of action reduces the likelihood of bacterial resistance developing to almost nil.
The public is aware of the Ebola virus threat, but may not be as aware of today’s deadly bacteria. Among the deadliest of resistant bacteria and a major threat to public health is Carbapenem-resistant Klebsiella pneumonia, or CRKP. Cellceutix has been targeting this bacteria and expects to shortly release its study findings. The drug, if successful, would be a major breakthrough.
Cellceutix in approximately one and a half months expects to have have top-line data from its Phase 2b trial of its antibiotic Brilacidin for Acute Bacterial Skin and Skin Structure Infections. Cellceutix believes this Presidential Order could not arrive at a better time and is optimistic that the data from the trial will demonstrate that its novel defensin-mimetic platform shreds bacteria quickly with little-to-no chance of resistance developing. Cellceutix believes positive data will position it perfectly to move forward quickly not only with Brilacidin, but its entire defensin-mimetic portfolio with support from the new Presidential Order.
“If we achieve successful data from the recently completed Phase 2 trial, my hope is that people will understand the defensin mimetic’s potential. It’s no longer a world class antibiotic drug, but a world class platform to fight serious public health threats,” commented Leo Ehrlich, Chief Executive Officer of Cellceutix.
Cellceutix to President Obama: We Have The Tools And Will Rise Up To The Challenge To Prevent Antibiotic Resistant Bacteria Becoming A Serious Threat to Public Health
BEVERLY, MA--(Marketwired - Sep 19, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, commends President Barack Obama for signing an Executive Order on Thursday, September 18, ordering federal agencies to launch a concerted effort to combat the growing threat from bacteria that is resistant to antibiotic treatment. The Obama administration’s measures are part of the first major federal effort to confront a public health problem that takes at least 23,000 lives a year and has an estimated annual impact of on the national economy of $20 billion in excess direct health care costs.
See New Executive Actions to Combat Antibiotic Resistance and Protect Public Health: http://www.whitehouse.gov/blog/2014/09/18/new-executive-actions-combat-antibiotic-resistance-and-protect-public-health
Cellceutix may have one of the world’s best technologies for combating antibiotic resistant bacteria in its novel class of antibiotics called defensin mimetics. They are modeled after host defense proteins, the front line of defense in the innate human immune system. The drug destroys bacteria just like the body would naturally by penetrating the bacterial cell wall, rather than via a biochemical approach like most classes of antibiotics do today. This unique mechanism of action reduces the likelihood of bacterial resistance developing to almost nil.
The public is aware of the Ebola virus threat, but may not be as aware of today’s deadly bacteria. Among the deadliest of resistant bacteria and a major threat to public health is Carbapenem-resistant Klebsiella pneumonia, or CRKP. Cellceutix has been targeting this bacteria and expects to shortly release its study findings. The drug, if successful, would be a major breakthrough.
Cellceutix in approximately one and a half months expects to have have top-line data from its Phase 2b trial of its antibiotic Brilacidin for Acute Bacterial Skin and Skin Structure Infections. Cellceutix believes this Presidential Order could not arrive at a better time and is optimistic that the data from the trial will demonstrate that its novel defensin-mimetic platform shreds bacteria quickly with little-to-no chance of resistance developing. Cellceutix believes positive data will position it perfectly to move forward quickly not only with Brilacidin, but its entire defensin-mimetic portfolio with support from the new Presidential Order.
“If we achieve successful data from the recently completed Phase 2 trial, my hope is that people will understand the defensin mimetic’s potential. It’s no longer a world class antibiotic drug, but a world class platform to fight serious public health threats,” commented Leo Ehrlich, Chief Executive Officer of Cellceutix.
Cellceutix to President Obama: We Have The Tools And Will Rise Up To The Challenge To Prevent Antibiotic Resistant Bacteria Becoming A Serious Threat to Public Health
BEVERLY, MA--(Marketwired - Sep 19, 2014) - Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, commends President Barack Obama for signing an Executive Order on Thursday, September 18, ordering federal agencies to launch a concerted effort to combat the growing threat from bacteria that is resistant to antibiotic treatment. The Obama administration’s measures are part of the first major federal effort to confront a public health problem that takes at least 23,000 lives a year and has an estimated annual impact of on the national economy of $20 billion in excess direct health care costs.
See New Executive Actions to Combat Antibiotic Resistance and Protect Public Health: http://www.whitehouse.gov/blog/2014/09/18/new-executive-actions-combat-antibiotic-resistance-and-protect-public-health
Cellceutix may have one of the world’s best technologies for combating antibiotic resistant bacteria in its novel class of antibiotics called defensin mimetics. They are modeled after host defense proteins, the front line of defense in the innate human immune system. The drug destroys bacteria just like the body would naturally by penetrating the bacterial cell wall, rather than via a biochemical approach like most classes of antibiotics do today. This unique mechanism of action reduces the likelihood of bacterial resistance developing to almost nil.
The public is aware of the Ebola virus threat, but may not be as aware of today’s deadly bacteria. Among the deadliest of resistant bacteria and a major threat to public health is Carbapenem-resistant Klebsiella pneumonia, or CRKP. Cellceutix has been targeting this bacteria and expects to shortly release its study findings. The drug, if successful, would be a major breakthrough.
Cellceutix in approximately one and a half months expects to have have top-line data from its Phase 2b trial of its antibiotic Brilacidin for Acute Bacterial Skin and Skin Structure Infections. Cellceutix believes this Presidential Order could not arrive at a better time and is optimistic that the data from the trial will demonstrate that its novel defensin-mimetic platform shreds bacteria quickly with little-to-no chance of resistance developing. Cellceutix believes positive data will position it perfectly to move forward quickly not only with Brilacidin, but its entire defensin-mimetic portfolio with support from the new Presidential Order.
“If we achieve successful data from the recently completed Phase 2 trial, my hope is that people will understand the defensin mimetic’s potential. It’s no longer a world class antibiotic drug, but a world class platform to fight serious public health threats,” commented Leo Ehrlich, Chief Executive Officer of Cellceutix.
Up 21 cents for the week. Not bad. Enjoy the weekend.eom
To the medical professionals on the board, can B-OM
be a replacement for the antibiotic mouthwash chlorhexidine. Gingivitis and periodontal disease is a huge market for antibiotic mouthwash and what the market offers today is only semi effective.
Thanks and have a great weekend.
CTIX NEWS..Bold statement to Obama...eom
CTIX NEWS. Talking to Obama!!!!....eom
CTIX NEWS.. Bold statement to Obama!!...eom
Rmzport, absolutely 100% agree. Instead of advisors, make them BOD...eom
Otc CTIX LONG TERM HOLD. Multi-Multi bagger
Now the rally is strengthened by numerous factors.
A key near-term catalyst is fast approaching with Brilacidin PIIb results.
Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol
This pre-catalyst buying volume and rally, suggests to seasoned investors that news is out that the Brilacidin 2b trial was successful.
We have word that there are many in the medical and scientific community very excited about Brilacidin-OM Phase 2B trial expected to start in 1 or 2 months
New Clinical Trial start catalysts are approaching for three drugs, Prurisol Phase 2/3 for Psoriasis, Kevetrin 1b for Leukemia(AML), Brilacidin OM phase 2B.
Up-listing plans, financing already in place for up-coming trials, and strong possibility of a partnership on positive Brilacidin PIIb results.
Flagship cancer drug Kevetrin is at a high dose, well past the dosing level range believed therapeutic, and an almost certain successful clinical trial primary outcome of safety.
On positive Brilacidin PIIb trial results, all technical chart bets are off. News trumps charts.
Awesome 10K http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis
Otc CTIX 2.42 Now the rally is strengthened by numerous factors.
A key near-term catalyst is fast approaching with Brilacidin PIIb results.
Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol
This pre-catalyst buying volume and rally, suggests to seasoned investors that news is out that the Brilacidin 2b trial was successful.
We have word that there are many in the medical and scientific community very excited about Brilacidin-OM Phase 2B trial expected to start in 1 or 2 months
New Clinical Trial start catalysts are approaching for three drugs, Prurisol Phase 2/3 for Psoriasis, Kevetrin 1b for Leukemia(AML), Brilacidin OM phase 2B.
Up-listing plans, financing already in place for up-coming trials, and strong possibility of a partnership on positive Brilacidin PIIb results.
Flagship cancer drug Kevetrin is at a high dose, well past the dosing level range believed therapeutic, and an almost certain successful clinical trial primary outcome of safety.
On positive Brilacidin PIIb trial results, all technical chart bets are off. News trumps charts.
Awesome 10K http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis
Otc CTIX 2.42 Now the rally is strengthened by numerous factors.
A key near-term catalyst is fast approaching with Brilacidin PIIb results.
Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol
This pre-catalyst buying volume and rally, suggests to seasoned investors that news is out that the Brilacidin 2b trial was successful.
We have word that there are many in the medical and scientific community very excited about Brilacidin-OM Phase 2B trial expected to start in 1 or 2 months
New Clinical Trial start catalysts are approaching for three drugs, Prurisol Phase 2/3 for Psoriasis, Kevetrin 1b for Leukemia(AML), Brilacidin OM phase 2B.
Up-listing plans, financing already in place for up-coming trials, and strong possibility of a partnership on positive Brilacidin PIIb results.
Flagship cancer drug Kevetrin is at a high dose, well past the dosing level range believed therapeutic, and an almost certain successful clinical trial primary outcome of safety.
On positive Brilacidin PIIb trial results, all technical chart bets are off. News trumps charts.
Awesome 10K http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis
BEST LONG TERM 3-5 years OTC CTIX 2.42 Now the rally is strengthened by numerous factors.
A key near-term catalyst is fast approaching with Brilacidin PIIb results.
Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol
This pre-catalyst buying volume and rally, suggests to seasoned investors that news is out that the Brilacidin 2b trial was successful.
We have word that there are many in the medical and scientific community very excited about Brilacidin-OM Phase 2B trial expected to start in 1 or 2 months
New Clinical Trial start catalysts are approaching for three drugs, Prurisol Phase 2/3 for Psoriasis, Kevetrin 1b for Leukemia(AML), Brilacidin OM phase 2B.
Up-listing plans, financing already in place for up-coming trials, and strong possibility of a partnership on positive Brilacidin PIIb results.
Flagship cancer drug Kevetrin is at a high dose, well past the dosing level range believed therapeutic, and an almost certain successful clinical trial primary outcome of safety.
On positive Brilacidin PIIb trial results, all technical chart bets are off. News trumps charts.
Awesome 10K http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis
Otc CTIX 2.43 Now the rally is strengthened by numerous factors.
A key near-term catalyst is fast approaching with Brilacidin PIIb results.
Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol
This pre-catalyst buying volume and rally, suggests to seasoned investors that news is out that the Brilacidin 2b trial was successful.
We have word that there are many in the medical and scientific community very excited about Brilacidin-OM Phase 2B trial expected to start in 1 or 2 months
New Clinical Trial start catalysts are approaching for three drugs, Prurisol Phase 2/3 for Psoriasis, Kevetrin 1b for Leukemia(AML), Brilacidin OM phase 2B.
Up-listing plans, financing already in place for up-coming trials, and strong possibility of a partnership on positive Brilacidin PIIb results.
Flagship cancer drug Kevetrin is at a high dose, well past the dosing level range believed therapeutic, and an almost certain successful clinical trial primary outcome of safety.
On positive Brilacidin PIIb trial results, all technical chart bets are off. News trumps charts.
Awesome 10K http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis
Otc CTIX 2.43 Now the rally is strengthened by numerous factors.
A key near-term catalyst is fast approaching with Brilacidin PIIb results.
Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol
This pre-catalyst buying volume and rally, suggests to seasoned investors that news is out that the Brilacidin 2b trial was successful.
We have word that there are many in the medical and scientific community very excited about Brilacidin-OM Phase 2B trial expected to start in 1 or 2 months
New Clinical Trial start catalysts are approaching for three drugs, Prurisol Phase 2/3 for Psoriasis, Kevetrin 1b for Leukemia(AML), Brilacidin OM phase 2B.
Up-listing plans, financing already in place for up-coming trials, and strong possibility of a partnership on positive Brilacidin PIIb results.
Flagship cancer drug Kevetrin is at a high dose, well past the dosing level range believed therapeutic, and an almost certain successful clinical trial primary outcome of safety.
On positive Brilacidin PIIb trial results, all technical chart bets are off. News trumps charts.
Awesome 10K http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis
Otc CTIX 2.43 Now the rally is strengthened by numerous factors.
A key near-term catalyst is fast approaching with Brilacidin PIIb results.
Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol
This pre-catalyst buying volume and rally, suggests to seasoned investors that news is out that the Brilacidin 2b trial was successful.
We have word that there are many in the medical and scientific community very excited about Brilacidin-OM Phase 2B trial expected to start in 1 or 2 months
New Clinical Trial start catalysts are approaching for three drugs, Prurisol Phase 2/3 for Psoriasis, Kevetrin 1b for Leukemia(AML), Brilacidin OM phase 2B.
Up-listing plans, financing already in place for up-coming trials, and strong possibility of a partnership on positive Brilacidin PIIb results.
Flagship cancer drug Kevetrin is at a high dose, well past the dosing level range believed therapeutic, and an almost certain successful clinical trial primary outcome of safety.
On positive Brilacidin PIIb trial results, all technical chart bets are off. News trumps charts.
Awesome 10K http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis